Evidence map›Paper›PMID 41782880›Full record

ArticleFrontiers in immunology2026

Unraveling the role of LINC02657 in clear cell renal cell carcinoma: insights into tumor aggression, immune modulation, and treatment response.

Juncheng Tong, Yang Liu, Aifa Tang, Xiangguo Xiong, Lifang Liu, Zhenqing Fan, Cheng Qian, Hongbing Mei, Han Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juncheng Tong *Luohu Clinical College of Shantou University Medical College, Shantou University Medical College, Shantou, Guangdong, China.
Yang Liu *Department of Oncology, Yantian District People's Hospital, Shenzhen, Guangdong, China.
Aifa Tang *Science and Educational Center, Luohu Hospital Group, The third Affiliated Hospital of Shenzhen University Shenzhen, Shenzhen, Guangdong, China.
Xiangguo Xiong *Department of Urinary Surgery, Lianping County People's Hospital, Heyuan, Guangdong, China.
Lifang LiuLuohu Clinical College of Shantou University Medical College, Shantou University Medical College, Shantou, Guangdong, China.
Zhenqing FanLuohu Clinical College of Shantou University Medical College, Shantou University Medical College, Shantou, Guangdong, China.
Cheng QianLuohu Clinical College of Shantou University Medical College, Shantou University Medical College, Shantou, Guangdong, China.
Hongbing MeiDepartment of Urinary Surgery, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.
Han WangDepartment of Urinary Surgery, Shenzhen Second People's Hospital, the First Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The role of long non-coding RNA LINC02657 in clear cell renal cell carcinoma (ccRCC) is poorly defined. This study aims to characterize its expression, clinical relevance, and oncogenic functions in ccRCC. Methods: We analyzed LINC02657 expression in pan-cancer and ccRCC cohorts from TCGA and ICGC. Prognostic value for overall (OS) and disease-specific survival (DSS) was evaluated using Kaplan-Meier and multivariate Cox regression. Functional mechanisms were investigated via Gene Set Enrichment Analysis (GSEA) and Results: LINC02657 was significantly upregulated in ccRCC tissues. High LINC02657 expression predicted poorer OS and DSS and was an independent prognostic factor for adverse outcomes. GSEA linked it to cell cycle regulation and mitotic checkpoint signaling. Functional experiments demonstrated that LINC02657 knockdown effectively inhibited ccRCC cell proliferation, migration, and invasion, and promoted reversal of EMT toward an epithelial phenotype. Additionally, its expression was associated with immune cell infiltration and checkpoint molecule levels. Drug sensitivity profiling indicated that low LINC02657 expression enhanced sensitivity to chemotherapy agents, including docetaxel, gemcitabine, and 5-fluorouracil. Conclusions: LINC02657 is a critical oncogenic lncRNA in ccRCC, promoting tumor progression by regulating cell cycle, EMT, and immune microenvironment. It serves as a robust independent prognostic biomarker and a potential therapeutic target, offering valuable insights for personalized ccRCC treatment strategies.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsRNA, Long NoncodingBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisBiomarkers, TumorRNA, Long Noncodingbiomarkersclear cell renal cell carcinomaLINC02657migrationproliferation

Identifiers

PMID41782880
PMCPMC12953511

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.